Alligator Bioscience
Alligator Bioscience is a Swedish biotech company focused on developing innovative antibody-based medicines for cancer immunotherapy. The company specializes in tumor-directed immunotherapies, leveraging its expertise in the CD40 field and antibody engineering technologies. Alligator aims to advance its drug candidates to Phase 2 clinical studies, making them attractive for out-licensing to Big Pharma for further development and commercialization. The company operates primarily from its headquarters in Lund, Sweden, and collaborates with Contract Development and Manufacturing Organizations (CDMOs) for production.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes tumor-directed therapies providing long-lasting immunity
Technologies for developing unique antibody-based treatments
Out-licensing of drug candidates to Big Pharma
Customers
Alligator Bioscience primarily targets large pharmaceutical companies interested in licensing innovative cancer immunotherapies. These partners are typically involved in the later stages of clinical development and commercialization. The company's drug candidates are designed to be attractive to Big Pharma due to their unique properties and potential for combination therapies. Alligator also collaborates with research institutions and biotech firms for early-stage development and technology sharing.
License drug candidates for late-stage development
Collaborate on early-stage development and technology
Engage in joint research on cancer immunotherapy
Strategy
Alligator Bioscience's strategic priorities include advancing its lead asset, mitazalimab, through clinical proof-of-concept in Phase 2 studies. The company focuses on out-licensing drug candidates to Big Pharma for further development and commercialization. Alligator aims to leverage its unique antibody engineering technologies to create differentiated therapies. Strategic partnerships and collaborations are key to expanding its pipeline and market reach.
To achieve clinical proof-of-concept
For further development by Big Pharma
To create differentiated therapies
Geography
Alligator Bioscience is headquartered in Lund, Sweden, and operates primarily within the European market. The company collaborates with international partners for clinical development and commercialization. Manufacturing is outsourced to Contract Development and Manufacturing Organizations (CDMOs) to leverage specialized expertise. Alligator's geographic focus allows it to maintain strong ties with European research institutions and biotech firms.
Risks
Alligator Bioscience faces several risks, including the uncertainty of clinical trial outcomes and reliance on partners for commercialization. The competitive landscape in immuno-oncology is intense, with rapid technological advancements. Financial risks include irregular cash flow from licensing agreements and the need for continuous funding. Geopolitical conflicts and market acceptance of new therapies also pose challenges.
- Clinical trial uncertaintyImpact: CriticalLikelihood: Medium
Outcomes are unpredictable
- Reliance on partnersImpact: HighLikelihood: Medium
For commercialization and development
- Intense competitionImpact: HighLikelihood: Medium
Rapid technological advancements
- Irregular cash flowImpact: MediumLikelihood: Medium
Dependent on licensing events
Accounting
Judgemental itemsFrom licensing agreements
Impact: Significant on reported revenue
To ensure accurate valuation of intangible assets
Impact: Critical for asset valuation
Affect international operations
Impact: Influences financial results
Similar listed companies
Publicly listed companies with a comparable business focus.
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Vimian Group
VIMIAN · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
Active Biotech
ACTI · Health Care
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications.
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Last updated: 24/09/2026